COVID-19 Home Testing Kit / SARS-CoV-2 Antigen Rapid Test Kit
The core protein of SARS-CoV-2 is the N protein (Nucleocapsid), which is a protein component located inside the virus. It is relatively conserved among β-coronaviruses and is often used as a tool for the diagnosis of coronaviruses. ACE2, as a key receptor for SARS-CoV-2 to enter cells, is of great significance for the research of viral infection mechanism.
- Non-invasive, simple to use
- Convenient, no devices required
- Rapid, get result in 15 minutes
- Stable, with high accuracy
- Inexpensive, cost-efficiency
The FDA has granted emergency use authorization (EUA) for antigen tests that can identify SARS-CoV-2. See FDA Authorizes Antigen Test to Rapid Detection of the Virus COVID-19
SARS-CoV-2 Antigen Rapid Test Kit Operation
SARS-CoV-2 Antigen Rapid Test Kit Instruction
FAQ
The SARS-CoV-2 Rapid Antigen Test is for use in point of care settings for both symptomatic and asymptomatic people. This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes.1 In addition, it serves as a valuable initial screening test for individuals that have been exposed to SARS-CoV-2 infected patients or a high risk environment.The test has a sensitivity of 96.52% and a specificity of 99.68%, based on 426 samples from two independent study centers.
A total of 253 participants were enrolled and 2 participants were excluded from the analyses due to invalid NP testing results. Of 251 participants (99.2%) that were included in the diagnostic accuracy analysis, a total of 201 participants (80.1%) had a Ct value ≤40. With Ct value 40 as the cut-off of NA testing, the sensitivity, specificity, and percent agreement of the FIC assay was 75.6% (95% CI 69.0%-81.3%), 100% (95% CI 91.1%-100%), and 80.5% (95% CI 75.1%-84.9%), respectively.
One type of rapid diagnostic test (RDT) detects the presence of viral proteins (antigens) expressed by the COVID-19 virus in a sample from the respiratory tract of a person. If the target antigen is present in sufficient concentrations in the sample, it will bind to specific antibodies fixed to a paper strip enclosed in a plastic casing and generate a visually detectable signal, typically within 30 minutes. The antigen(s) detected are expressed only when the virus is actively replicating; therefore, such tests are best used to identify acute or early infectionOne type of rapid diagnostic test (RDT) detects the presence of viral proteins (antigens) expressed by the COVID-19 virus in a sample from the respiratory tract of a person. If the target antigen is present in sufficient concentrations in the sample, it will bind to specific antibodies fixed to a paper strip enclosed in a plastic casing and generate a visually detectable signal, typically within 30 minutes. The antigen(s) detected are expressed only when the virus is actively replicating; therefore, such tests are best used to identify acute or early infection
Result available in 15 minutes.